Ciluprevir (BILN-2061)Inhibitor of HCV NS3 protease CAS# 300832-84-2 |
- Anguizole
Catalog No.:BCC1365
CAS No.:442666-98-0
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
- Balapiravir
Catalog No.:BCC1396
CAS No.:690270-29-2
- Nesbuvir
Catalog No.:BCC1796
CAS No.:691852-58-1
- PSI-6206
Catalog No.:BCC3609
CAS No.:863329-66-2
- RO-9187
Catalog No.:BCC1904
CAS No.:876708-03-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 300832-84-2 | SDF | Download SDF |
| PubChem ID | 6450803 | Appearance | Powder |
| Formula | C40H50N6O8S | M.Wt | 774.93 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| SMILES | CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3)OC)C(=C2)OC4CC5C(=O)NC6(CC6C=CCCCCCC(C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)O | ||
| Standard InChIKey | PJZPDFUUXKKDNB-CJXSQDHESA-N | ||
| Standard InChI | InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24?,27-,29+,33+,40-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Ciluprevir (BILN-2061) Dilution Calculator
Ciluprevir (BILN-2061) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2904 mL | 6.4522 mL | 12.9044 mL | 25.8088 mL | 32.261 mL |
| 5 mM | 0.2581 mL | 1.2904 mL | 2.5809 mL | 5.1618 mL | 6.4522 mL |
| 10 mM | 0.129 mL | 0.6452 mL | 1.2904 mL | 2.5809 mL | 3.2261 mL |
| 50 mM | 0.0258 mL | 0.129 mL | 0.2581 mL | 0.5162 mL | 0.6452 mL |
| 100 mM | 0.0129 mL | 0.0645 mL | 0.129 mL | 0.2581 mL | 0.3226 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ciluprevir is a selective inhibitor of NS3 protease with IC50 value of 3.0 nM [1].
NS3 (non-structural protein 3) protease is a protein whose C-terminal two-thirds contain a helicase and nucleic acid-stimulated NTPase activities and plays a pivotal role in HCV replication. It is reported that NS3 has regarded as a target to control HCV RNA replication via designing new drugs to inhibit it [2, 3].
Ciluprevir is a NS3 protease inhibitor and has a different affinity with the reported NS3 protease inhibitor VX-950. When using covalent adducts formation method, Svahn Gustafsson S found that ciluprevir showed faster association and slower dissociation kinetics [1].
NS3.4 protease inhibitor ciluprevir has potential for treating chronic HCV and robust antiviral activities have been reported. Furthermore, treatment HCV patients with ciluprevir showed significant HCV RNA reduction in plasma levels in clinical [4].
References:
[1]. Svahn Gustafsson, S., et al., Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants. J Med Chem, 2014. 57(5): p. 1802-11.
[2]. Howe, J.A., et al., Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin. Open Forum Infect Dis, 2014. 1(2): p. ofu078.
[3]. Susser, S., et al., Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir. Antimicrob Agents Chemother, 2015.
[4]. Goudreau, N. and M. Llinas-Brunet, The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin Investig Drugs, 2005. 14(9): p. 1129-44.
- RS 504393
Catalog No.:BCC1910
CAS No.:300816-15-3
- TG003
Catalog No.:BCC4416
CAS No.:300801-52-9
- BMS 309403
Catalog No.:BCC8046
CAS No.:300657-03-8
- HMBA Linker
Catalog No.:BCC2831
CAS No.:3006-96-0
- SKF 77434 hydrobromide
Catalog No.:BCC7144
CAS No.:300561-58-4
- Dehydrocorydalin
Catalog No.:BCN2474
CAS No.:30045-16-0
- Boc-Asn-ol
Catalog No.:BCC2587
CAS No.:30044-67-8
- Ro 28-1675
Catalog No.:BCC4124
CAS No.:300353-13-3
- Diphyllin O-glucoside
Catalog No.:BCN8065
CAS No.:30021-77-3
- HEAT hydrochloride
Catalog No.:BCC6683
CAS No.:30007-39-7
- Isoline
Catalog No.:BCN2063
CAS No.:30000-36-3
- Hypotaurine
Catalog No.:BCN1749
CAS No.:300-84-5
- GSA 10
Catalog No.:BCC6329
CAS No.:300833-95-8
- 4-CMTB
Catalog No.:BCC6250
CAS No.:300851-67-6
- Methyl Linolenate
Catalog No.:BCN8318
CAS No.:301-00-8
- Oleamide
Catalog No.:BCC6827
CAS No.:301-02-0
- Robinin
Catalog No.:BCN5208
CAS No.:301-19-9
- Malvidin-3-O-galactoside chloride
Catalog No.:BCN3030
CAS No.:30113-37-2
- Tianeptine sodium
Catalog No.:BCC2506
CAS No.:30123-17-2
- TCS 359
Catalog No.:BCC1183
CAS No.:301305-73-7
- CH 223191
Catalog No.:BCC3896
CAS No.:301326-22-7
- P7C3
Catalog No.:BCC6524
CAS No.:301353-96-8
- H-Val-NH2.HCl
Catalog No.:BCC3144
CAS No.:3014-80-0
- Seneganolide
Catalog No.:BCN5209
CAS No.:301530-12-1
Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.[Pubmed:17002221]
Curr Opin Drug Discov Devel. 2006 Sep;9(5):606-17.
Hepatitis C virus (HCV) NS3.4A protease inhibitors have potential for treating chronic HCV disease. Robust antiviral effects have been reported for the three HCV NS3.4A inhibitors (BILN-2061 (ciluprevir), telaprevir (VX-950; Vertex Pharmaceuticals Inc./Janssen Pharnmaceutica NV/Mitsubishi Pharma Corp.) and SCH-503034; Schering-Plough Research Institute) that have been studied in clinical trials to date in HCV-infected patients, and new inhibitor molecules continue to appear on the horizon. Herein, toe relate the remarkable progress of these drug candidates to recent evidence that suggests HCV might depend on NS3.4A protease to subvert multiple innate cellular defense mechanisms.
